TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17113671

Group type: EXPERIMENTAL
Intervention: Monte Carlo system (MCDE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Superposition convolution systems (TMS and Pinnacle)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All planning systems (Monte Carlo, TMS, Pinnacle)
Number of subjects: 10
Study: 15310780

Group type: EXPERIMENTAL
Intervention: Prophylactic hematopoietic colony-stimulating factors (CSFs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (placebo or no therapy)
Number of subjects: 16
Study: 11497229

Group type: EXPERIMENTAL
Intervention: New cytotoxic drugs (vinorelbine, paclitaxel, docetaxel, gemcitabine, irinotecan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of cisplatin and newer drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel and other newer drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer drug combinations
Number of subjects: 0
Study: 9462204

Group type: EXPERIMENTAL
Intervention: LAC (30 mg of lansoprazole twice daily + 1 g of amoxycillin twice daily + 400 mg of metronidazole twice daily)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: LAM (30 mg of lansoprazole twice daily + 1 g of amoxycillin twice daily + 250 mg of clarithromycin twice daily)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: LCM (30 mg of lansoprazole twice daily + 400 mg of metronidazole twice daily + 250 mg of clarithromycin twice daily)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: OAM (20 mg of omeprazole twice daily + 1 g of amoxycillin twice daily + 400 mg of metronidazole twice daily)
Number of subjects: 496
Study: 7945617

Group type: EXPERIMENTAL
Intervention: Umbilical venous pressure (UVP) measurement
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Preload index (PLI) assessment of reversed IVC blood flow
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Estimate of abnormal UVP based on PLI
Number of subjects: 113
Study: 3285732

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine/0.0002% fentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 80
Study: 30487974

Group type: EXPERIMENTAL
Intervention: Mealtime insulin aspart
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bedtime insulin detemir
Number of subjects: 40
Study: 26837800

Group type: EXPERIMENTAL
Intervention: Competence feedback group (CFG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study: 25537011

Group type: EXPERIMENTAL
Intervention: Tideglusib 1000 mg QD
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Tideglusib 1000 mg QOD
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Tideglusib 500 mg QD
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 23522973

Group type: EXPERIMENTAL
Intervention: Radionuclide therapy (Samarium‐153 EDTMP), N=12
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no radionuclide therapy), N=12
Number of subjects: 24
Study: 20693354

Group type: EXPERIMENTAL
Intervention: Insulin aspart administered 15 min before mealtime
Number of subjects: 10
Study: 18439244

Group type: EXPERIMENTAL
Intervention: Assessment of personality disorders and individual feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: General life situation interview
Number of subjects: 0
Study: 16644913

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) performed, n = 49
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no assisted hatching), n = 54
Number of subjects: 103
Study: 12826500

Group type: EXPERIMENTAL
Intervention: Captopril (administered 8 hours and 1 hour before coronary angiography)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no captopril treatment)
Number of subjects: 80
Study: 11196396

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 1 week, increased to 40 mg/day for the following weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day plus local application of lidocaine ointment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fluoxetine alone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fluoxetine plus lidocaine ointment
Number of subjects: 43
Study: 8992100

Group type: EXPERIMENTAL
Intervention: Cefixime 8 mg/kg bodyweight once daily for 5 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Penicillin V 20,000 I.U./kg bodyweight t.i.d. for 10 days
Number of subjects: 160
Study: 2001019

Group type: EXPERIMENTAL
Intervention: Desflurane 0.65 MAC
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isoflurane 0.65 MAC
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Desflurane 1.25 MAC
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isoflurane 1.25 MAC
Number of subjects: 28
Study: 6678822

Group type: EXPERIMENTAL
Intervention: Centbucridine (0.5%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lidocaine (2%)
Number of subjects: 120
Study: 30088055

Group type: EXPERIMENTAL
Intervention: LAL ablation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (EEPVI and roof line ablation)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LAL group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LAL group (without dyssynchrony)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LAL group (with dyssynchrony)
Number of subjects: 102
Study: 28629243

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 120
Study: 27232378

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 9
Study: 24755906

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times a day for 3 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 28
Study: 22640466

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study: 20586522

Group type: EXPERIMENTAL
Intervention: Pregabalin (300, 450, and 600 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18852414

Group type: EXPERIMENTAL
Intervention: IVT treatment followed by PDT
Number of subjects: 84

Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 84
Study: 17058733

Group type: EXPERIMENTAL
Intervention: 2-liter electrolyte lavage solution plus 20 mg of oral bisacodyl
Number of subjects: 300

Group type: COMPARATOR
Intervention: 4 liters of electrolyte lavage
Number of subjects: 300
Study: 12656935

Group type: EXPERIMENTAL
Intervention: Valproate (sodium valproate and valproic acid)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 38
Study: 10690133

Group type: EXPERIMENTAL
Intervention: rapacuronium 1.5 mg kg‐1
Number of subjects: 56

Group type: COMPARATOR
Intervention: vecuronium 0.1 mg kg‐1
Number of subjects: 56

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 56
Study: 8739020

Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 1.0 mg and higher
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral quinapril 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 10 mg and oral quinapril 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 12
Study: 1763919

Group type: EXPERIMENTAL
Intervention: Starr‐Edwards prosthesis (Group A)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Saint Jude prosthesis (Group B)
Number of subjects: 236
Study: 6352533

Group type: EXPERIMENTAL
Intervention: 1% tolnaftate cream
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 3% undecylenic acid and its zinc salt cream
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 97
Study: 30015785

Group type: EXPERIMENTAL
Intervention: Child‐ and Family‐focused Cognitive‐Behavioral Therapy (CFF‐CBT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 71
Study: 28112799

Group type: EXPERIMENTAL
Intervention: Oxymatrine (0.6 g per day for 8 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Acitretin (0.75 mg kg‐1 per day from week 0 to week 2 and 20‐30 mg per day from week 3 to week 8)
Number of subjects: 67
Study: 26577964

Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 140

Group type: COMPARATOR
Intervention: Clipping
Number of subjects: 140
Study: 22257685

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 2569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2569
Study: 21743374

Group type: EXPERIMENTAL
Intervention: Codeine (as needed basis)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype (PMs and UMs)
Number of subjects: 45
Study: 18398801

Group type: EXPERIMENTAL
Intervention: Augmentation with atypical antipsychotics (AAP), particularly olanzapine; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Augmentation with atypical antipsychotics (AAP); specific dosage and duration not mentioned.
Number of subjects: 0
Study: 16547993

Group type: EXPERIMENTAL
Intervention: Three-dimensional sonography (3D US)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cholescintigraphy
Number of subjects: 35
Study: 12663011

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin 0.3%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of aqueous humor concentrations of ciprofloxacin and ofloxacin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of intravitreal concentrations of ciprofloxacin and ofloxacin
Number of subjects: 18
Study: 11400186

Group type: COMPARATOR
Intervention: (R)‐carvedilol 12.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: (S)‐carvedilol 12.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: (R,S)‐carvedilol 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 12
Study: 9257784

Group type: EXPERIMENTAL
Intervention: mSRW (mean, 23.8 microg of Amb a 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: mSRW
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: mSRW (high doses >20 microg of Amb a 1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8292063

Group type: EXPERIMENTAL
Intervention: 4 mg dimetindene
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8 mg dimetindene
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3487668

Group type: EXPERIMENTAL
Intervention: Selective distal splenorenal shunt (DSRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total shunt (H-graft interposition total shunt)
Number of subjects: 0
Study: 30572458

Group type: EXPERIMENTAL
Intervention: Expert proctoring
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 45

Group type: COMPARATOR
Intervention: Independent training
Number of subjects: 45
Study: 27591093

Group type: EXPERIMENTAL
Intervention: Healthy individuals
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Individuals with unilateral ZMC fracture
Number of subjects: 36
Study: 24944136

Group type: EXPERIMENTAL
Intervention: Street football training (FG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 22
Study: 23991622

Group type: EXPERIMENTAL
Intervention: Prasugrel (30 mg loading dose before angiography, additional 30 mg at PCI if indicated)
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Prasugrel (pretreatment)
Number of subjects: 4033

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 4033
Study: 21414048

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with gradual updosing to 800 mg of protein (5 peanuts/day) followed by 30-week maintenance
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with gradual updosing
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 22
Study: 18806534

Group type: EXPERIMENTAL
Intervention: Topical fentanyl plus dexpanthenol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexpanthenol
Number of subjects: 40
Study: 16814058

Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring (ISCR) in Group 1 (179 patients)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (Group 2, 101 patients without ISCR)
Number of subjects: 280
Study: 12882850

Group type: EXPERIMENTAL
Intervention: Mediterranean Lifestyle Program (MLP)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 279
Study: 10995003

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (1.5 g/m2, 2.25 g/m2, or 3 g/m2 every 2 weeks for three doses)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fludarabine (25 mg/m2/day for 5 days every 4 weeks for six cycles)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fludarabine followed by high-dose cyclophosphamide
Number of subjects: 25
Study: 8630632

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg once daily
Number of subjects: 379

Group type: COMPARATOR
Intervention: Naproxen 750 mg daily
Number of subjects: 379
Study: 1467811

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.5 mg i.v.)
Number of subjects: 64
Study: 3849459

Group type: EXPERIMENTAL
Intervention: Pancreatin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of Pancreatin and Cimetidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: No treatment (previous studies)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy subjects (previous studies)
Number of subjects: 8
Study: 31875756

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 46

Group type: COMPARATOR
Intervention: All groups (Dexmedetomidine, Propofol, Midazolam)
Number of subjects: 46
Study: 30388128

Group type: EXPERIMENTAL
Intervention: Infants with low‐educated mothers
Number of subjects: 2513

Group type: COMPARATOR
Intervention: Infants with high‐educated mothers
Number of subjects: 2513
Study: 27185505

Group type: EXPERIMENTAL
Intervention: Bi-lingual breastfeeding education on a touch screen computer program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Printed educational material (Control)
Number of subjects: 46
Study: 24752311

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 209

Group type: COMPARATOR
Intervention: repaglinide
Number of subjects: 209
Study: 21741883

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 19942263

Group type: EXPERIMENTAL
Intervention: Investigator training for prostate biopsy collection emphasizing core length and number of cores obtained.
Number of subjects: 4649

Group type: COMPARATOR
Intervention: Entry biopsies (before investigator training).
Number of subjects: 4649
Study: 19029215

Group type: EXPERIMENTAL
Intervention: 0.2% ropivocaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 17012980

Group type: EXPERIMENTAL
Intervention: Adjunctive quetiapine (<400 mg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 14656032

Group type: EXPERIMENTAL
Intervention: High-dose vitamin therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-dose vitamin therapy
Number of subjects: 50
Study: 11303312

Group type: EXPERIMENTAL
Intervention: Patients with nephrotic syndrome (subgroup I/A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 57
Study: 8965152

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (APAP/C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1464159

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment during intensive consolidation
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Folate (F) levels during treatment
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Event-free survival correlation with RBC MTX levels
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: RBC MTX and RBC F levels during maintenance therapy
Number of subjects: 224
Study: 6144241

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31738483

Group type: EXPERIMENTAL
Intervention: Lower-target group (LDL cholesterol < 70 mg/dL)
Number of subjects: 2860

Group type: COMPARATOR
Intervention: Higher-target group (LDL cholesterol 90-110 mg/dL)
Number of subjects: 2860
Study: 30763799

Group type: EXPERIMENTAL
Intervention: Severe depression subtype
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Moderate depression with anxiety subtype
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Mild depression with anxiety/somatization subtype
Number of subjects: 375
Study: 28150964

Group type: EXPERIMENTAL
Intervention: 3 months of CACR
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 6 months of CACR
Number of subjects: 98
Study: 26084138

Group type: EXPERIMENTAL
Intervention: Tramadol (1.5 mg/kg loading dose and patient-controlled analgesia for 1 day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol (1 g intravenously 30 min before the end of the operation and 1 g each day at 6‐h intervals)
Number of subjects: 0
Study: 23144370

Group type: EXPERIMENTAL
Intervention: High-tension group (n = 44)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-tension group (n = 46)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n = 60)
Number of subjects: 90
Study: 21527040

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 6
Study: 18632258

Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol (400 mcg and 24 mcg/day, respectively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide (800 mcg/day)
Number of subjects: 0
Study: 16926575

Group type: EXPERIMENTAL
Intervention: Tender point examination (TP) in women with VVS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (nonaffected women)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pain history and interference assessments in women with VVS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pain behaviors in women with VVS
Number of subjects: 16
Study: 14620469

Group type: EXPERIMENTAL
Intervention: Upper-body cooling (UC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Upper-body cooling combined with leg heating (UCLH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 11125148

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor physostigmine
Number of subjects: 0
Study: 9013229

Group type: EXPERIMENTAL
Intervention: Treatment according to protocol
Number of subjects: 148
Study: 1575333

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg and 1.0 mg/kg 3 min later)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thiopental (5.0 mg/kg and 2.0 mg/kg 3 min later)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 12
Study: 3976960

Group type: EXPERIMENTAL
Intervention: Attributable benefit or risk information
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Relative risk information
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (no data)
Number of subjects: 318
Study: 31939265

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) applied perineally, 3000 pulses weekly for four consecutive weeks, energy flux density 0.25 mJ/mm2, frequency 4 Hz
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo treatment with a non-functional handpiece
Number of subjects: 62
Study: 29530260

Group type: EXPERIMENTAL
Intervention: Retrieval Cues (RCs) presented during exposure
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Retrieval Cues (RCs) perceived as comforting (safety signals)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No Retrieval Cues (Control group)
Number of subjects: 65
Study: 27526146

Group type: EXPERIMENTAL
Intervention: BioPQQ™ (20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25645368

Group type: EXPERIMENTAL
Intervention: Patient report
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Clinician report
Number of subjects: 756
Study: 24429126

Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol 110 μg and glycopyrronium 50 μg)
Number of subjects: 2224

Group type: COMPARATOR
Intervention: Glycopyrronium (50 μg)
Number of subjects: 2224

Group type: COMPARATOR
Intervention: Tiotropium (18 μg)
Number of subjects: 2224
Study: 21905970

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg and 90 mg
Number of subjects: 0
Study: 19011432

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 16870690

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12055461

Group type: EXPERIMENTAL
Intervention: No retinopexy (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transscleral cryotherapy (group 2)
Number of subjects: 60